Last reviewed · How we verify

Gemcitabine + cisplatin + albumin-bound paclitaxel

AstraZeneca · Phase 3 active Small molecule

Gemcitabine + cisplatin + albumin-bound paclitaxel is a Chemotherapy combination (nucleoside analog + platinum agent + taxane) Small molecule drug developed by AstraZeneca. It is currently in Phase 3 development for Metastatic pancreatic cancer, Non-small cell lung cancer, Ovarian cancer. Also known as: Background gemcitabine-based chemotherapy Regimen, This regimen is not allowed for countries in the European Union..

This combination uses three chemotherapy agents that work together to damage cancer cell DNA and disrupt cell division through different mechanisms.

This combination uses three chemotherapy agents that work together to damage cancer cell DNA and disrupt cell division through different mechanisms. Used for Metastatic pancreatic cancer, Non-small cell lung cancer, Ovarian cancer.

At a glance

Generic nameGemcitabine + cisplatin + albumin-bound paclitaxel
Also known asBackground gemcitabine-based chemotherapy Regimen, This regimen is not allowed for countries in the European Union.
SponsorAstraZeneca
Drug classChemotherapy combination (nucleoside analog + platinum agent + taxane)
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 3

Mechanism of action

Gemcitabine is a nucleoside analog that inhibits ribonucleotide reductase and gets incorporated into DNA, causing chain termination. Cisplatin is a platinum-based alkylating agent that forms DNA cross-links, preventing replication. Albumin-bound paclitaxel stabilizes microtubules to prevent mitotic spindle formation. Together, these agents provide synergistic cytotoxic effects against rapidly dividing cancer cells.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Gemcitabine + cisplatin + albumin-bound paclitaxel

What is Gemcitabine + cisplatin + albumin-bound paclitaxel?

Gemcitabine + cisplatin + albumin-bound paclitaxel is a Chemotherapy combination (nucleoside analog + platinum agent + taxane) drug developed by AstraZeneca, indicated for Metastatic pancreatic cancer, Non-small cell lung cancer, Ovarian cancer.

How does Gemcitabine + cisplatin + albumin-bound paclitaxel work?

This combination uses three chemotherapy agents that work together to damage cancer cell DNA and disrupt cell division through different mechanisms.

What is Gemcitabine + cisplatin + albumin-bound paclitaxel used for?

Gemcitabine + cisplatin + albumin-bound paclitaxel is indicated for Metastatic pancreatic cancer, Non-small cell lung cancer, Ovarian cancer.

Who makes Gemcitabine + cisplatin + albumin-bound paclitaxel?

Gemcitabine + cisplatin + albumin-bound paclitaxel is developed by AstraZeneca (see full AstraZeneca pipeline at /company/astrazeneca).

Is Gemcitabine + cisplatin + albumin-bound paclitaxel also known as anything else?

Gemcitabine + cisplatin + albumin-bound paclitaxel is also known as Background gemcitabine-based chemotherapy Regimen, This regimen is not allowed for countries in the European Union..

What drug class is Gemcitabine + cisplatin + albumin-bound paclitaxel in?

Gemcitabine + cisplatin + albumin-bound paclitaxel belongs to the Chemotherapy combination (nucleoside analog + platinum agent + taxane) class. See all Chemotherapy combination (nucleoside analog + platinum agent + taxane) drugs at /class/chemotherapy-combination-nucleoside-analog-platinum-agent-taxane.

What development phase is Gemcitabine + cisplatin + albumin-bound paclitaxel in?

Gemcitabine + cisplatin + albumin-bound paclitaxel is in Phase 3.

What are the side effects of Gemcitabine + cisplatin + albumin-bound paclitaxel?

Common side effects of Gemcitabine + cisplatin + albumin-bound paclitaxel include Neutropenia, Anemia, Thrombocytopenia, Nausea/vomiting, Peripheral neuropathy, Fatigue.

Related